The White House plans to remove the FDA commissioner, potentially disrupting regulatory policies amid ongoing market-sensitive drug approvals.
President Donald Trump has approved a decision to dismiss U.S. Food and Drug Administration Commissioner Marty Makary, sources said. The move comes as the FDA oversees critical drug and medical device approvals, including those tied to public health and biotech sectors.
Makary, who has led the agency since early 2023, has been involved in high-profile decisions affecting pharmaceutical stocks and healthcare ETFs. His potential replacement could shift regulatory priorities, particularly in areas like drug pricing and emergency use authorizations.
Markets have closely monitored FDA leadership changes for their impact on biotech valuations and healthcare policy. No immediate reaction was reported in futures or sector-specific equities.